Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Machine Learning in the Differentiation of Follicular Lymphoma from Diffuse Large B-cell Lymphoma with Radiomic [18F]FDG PET/CT Features
Filipe Montes de Jesus, Yunchao Yin, Elissavet Mantzorou-Kyriaki, Xaver Kahle, Robbert de Haas, Derya Yakar, Andor W.J.M. Glaudemans, Walter Noordzij, Thomas Kwee, Marcel Nijland
Borrelia burgdorferi mimicking central nervous system relapse in diffuse large B cell lymphoma
Published in: Annals of Hematology
Access to document
10.1007/s00277-020-04022-5
document
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial
Published in: Haematologica
Access to document
10.3324/haematol.2019.238162
document
Patients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients withoutMYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in...
Martine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, Katerina Bakunina, Rogier Mous, Pieternella J Lugtenburg, Daan Dierickx, Gustaaf W van Imhoff, Joost S P Vermaat, Erik A F Marijt, Otto Visser, Caroline Mandigers, Yavuz M Bilgin, Aart Beeker, Mark F Durian, Bas van Rees, Lara H Bohmer, Lidwine W Tick, Rinske S Boersma, Tjeerd J F SnijdersHarry C Schouten, Harry R Koene, Eva de Jongh, Nathalie Hijmering, Arjan Diepstra, Anke van den Berg, Anne I J Arens, Julia Huijbregts, Otto Hoekstra, Josee M Zijlstra, Daphne de Jong, Marie José Kersten
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)
Published in: Journal of Clinical Oncology
Access to document
10.1200/JCO.19.03418
document
PURPOSEImmunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). This randomized trial assessed whether rituximab intensification during the first 4 cycles of R-CHOP could improve the outcome of these patients compared with standard R-CHOP.PATIENTS AND METHODSA total of 574 patients with DLBCL age 18 to 80 years were randomly assigned to induction therapy with 6 or 8 cycles of R-CHOP-14 with (RR-CHOP-14) or without (R-CHOP-14) intensification of rituximab in the first 4 cycles. The...
Pieternella Johanna Lugtenburg, Peter de Nully Brown, Bronno van der Holt, Francesco A. D'Amore, Harry R. Koene, Eva de Jongh, Rob Fijnheer, Joost W. van Esser, Lara H. Boehmer, Johannes F. Pruijt, Gregor E. Verhoef, Mels Hoogendoorn, Memis Y. Bilgin, Marcel Nijland, Nicole C. van der Burg-de Graauw, Margreet Oosterveld, Kon-Siong G. Jie, Thomas Stauffer Larsen, Marjolein W. van der Poel, Maria B. LeijsMatthijs H. Silbermann, Marinus van Marwijk Kooy, Aart Beeker, Marie J. Kersten, Jeanette K. Doorduijn, Lidwine W. Tick, Rolf E. Brouwer, King H. Lam, Coreline N. Burggraaff, Bart de Keizer, Anne I. Arens, Daphne de Jong, Otto S. Hoekstra, Josee M. Zijlstra-Baalbergen
Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study
Published in: Annals of Oncology
Access to document
10.1016/j.annonc.2020.04.014
document
Background: The impact of rituximab on health-related quality of life (HRQoL) in primary central nervous system lymphoma patients is not well known. We determined the impact of rituximab added to standard high-dose methotrexate-based treatment on HRQoL in patients in a large randomised trial. Patients and methods: Patients from a large phase III trial (HOVON 105/ALLG NHL 24), randomly assigned to receive standard chemotherapy with or without rituximab and followed by 30 Gy whole brain radiotherapy (WBRT) in patients ≤60 years, completed the EORTC QLQ-C30 and QLQ-BN20 questionnaires before...
M. van der Meulen, K. Bakunina, M. Nijland, M. C. Minnema, G. Cull, W. B. C. Stevens, J. W. Baars, K. D. Mason, A. Beeker, M. Beijert, M. J. B. Taphoorn, M. J. van den Bent, S. Issa, J. K. Doorduijn, J. E. C. Bromberg, L. Dirven